187 related articles for article (PubMed ID: 22935933)
21. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
22. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Böhme A; Shah PM; Stille W; Hoelzer D
Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
[TBL] [Abstract][Full Text] [Related]
23. Rapid recovery from acute kidney injury in a patient with metformin-associated lactic acidosis and hypothermia.
Mustafa E; Lai L; Lien YH
Am J Med; 2012 Feb; 125(2):e1-2. PubMed ID: 22269627
[No Abstract] [Full Text] [Related]
24. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?
Watkins RR; Deresinski S
Clin Infect Dis; 2017 Nov; 65(12):2137-2143. PubMed ID: 29020249
[TBL] [Abstract][Full Text] [Related]
25. Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review.
Platsouka E; Zissis NP; Portolos J; Paniara O
J Chemother; 2003 Feb; 15(1):27-30. PubMed ID: 12678410
[TBL] [Abstract][Full Text] [Related]
26. Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Horikoshi Y; Higuchi H; Suwa J; Isogai M; Shoji T; Ito K
J Infect Chemother; 2016 Aug; 22(8):532-5. PubMed ID: 27263807
[TBL] [Abstract][Full Text] [Related]
27. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
Pultz MJ; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
[TBL] [Abstract][Full Text] [Related]
29. Safety evaluation of piperacillin/tazobactam in very low birth weight infants.
Berger A; Kretzer V; Apfalter P; Rohrmeister K; Zaknun D; Pollak A
J Chemother; 2004 Apr; 16(2):166-71. PubMed ID: 15216952
[TBL] [Abstract][Full Text] [Related]
30. Moraxella lacunata septic arthritis in a patient with lupus nephritis.
Woodbury A; Jorgensen J; Owens A; Henao-Martinez A
J Clin Microbiol; 2009 Nov; 47(11):3787-8. PubMed ID: 19794049
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; Silvestri C; Di Matteo F; Abbruzzetti A; Scalise G; Saba V
Crit Care Med; 2008 Jan; 36(1):240-5. PubMed ID: 18090372
[TBL] [Abstract][Full Text] [Related]
32. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
Erasmo AA; Crisostomo AC; Yan LN; Hong YS; Lee KU; Lo CM
Asian J Surg; 2004 Jul; 27(3):227-35. PubMed ID: 15564167
[TBL] [Abstract][Full Text] [Related]
33. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Pillay T; Pillay DG; Adhikari M; Sturm AW
Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial stewardship in institutions and office practices.
Shah RC; Shah P
Indian J Pediatr; 2008 Aug; 75(8):815-20. PubMed ID: 18769893
[TBL] [Abstract][Full Text] [Related]
35. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Paladino JA; Gilliland-Johnson KK; Adelman MH; Cohn SM
Surg Infect (Larchmt); 2008 Jun; 9(3):325-33. PubMed ID: 18570574
[TBL] [Abstract][Full Text] [Related]
36. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of revised piperacillin-tazobactam breakpoints in CLSI M-100 S32.
Dash D; Rai S
Indian J Med Microbiol; 2023; 42():108-109. PubMed ID: 36241530
[No Abstract] [Full Text] [Related]
38. [Thoracic wall crossing (pseudo-?) tumor in a child: abscess-forming thoracic actinomycosis caused by Actinomyces meyeri et israeli].
Bark B; Perlick E; Stöver B
Rofo; 2004 Jan; 176(1):125-7. PubMed ID: 14712418
[No Abstract] [Full Text] [Related]
39. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
Harkless L; Boghossian J; Pollak R; Caputo W; Dana A; Gray S; Wu D
Surg Infect (Larchmt); 2005; 6(1):27-40. PubMed ID: 15865549
[TBL] [Abstract][Full Text] [Related]
40. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
